RxDoctor Payments Data

Spring Neihart

Psychiatric/Mental Health · Pocatello, IDNPI 1548999857

Payments from drug & device makers

$839in general payments, 2019–2025

Across 31 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$478
  • E.r. Squibb & Sons, L.L.C.$128
  • Otsuka America Pharmaceutical, Inc.$95
  • Teva Pharmaceuticals USA, Inc.$78
  • Alkermes, Inc.$24
  • Axsome Therapeutics, Inc.$19
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$839100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$839 in reported general payments places this provider in the 55th percentile of 221 psychiatric/mental health providers in Idaho.

See all psychiatric/mental health providers in Idaho

Medicare billing

Part B allowed, 2024
$7,604
Medicare patients
15
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl35$50,600
RexultiBrexpiprazole19$23,128
Aripiprazole27$4,525
Olanzapine18$4,095
Atomoxetine Hcl15$3,929
Bupropion XlBupropion Hcl26$1,706
Lurasidone Hcl13$1,367
Duloxetine Hcl22$1,335
Divalproex Sodium ErDivalproex Sodium29$1,288
Buspirone Hcl34$727
Venlafaxine Hcl ErVenlafaxine Hcl22$401
Prazosin Hcl16$324
Hydroxyzine Hcl26$287
Propranolol Hcl29$287
Clonazepam21$266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$478$50,60035 claims
Otsuka America Pharmaceutical, Inc.Rexulti$95$23,12819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 221 psychiatric/mental health providers in Idaho.

Other psychiatric/mental health in Pocatello

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →